Financial Performance - Operating revenue for the reporting period was ¥987,442,262.52, representing a year-on-year growth of 20.46%[9] - Net profit attributable to shareholders was ¥175,719,154.58, a significant increase of 390.88% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥131,492,153.84, up 83.71% year-on-year[9] - Basic earnings per share for the reporting period was ¥0.187, reflecting a 325.00% increase compared to the same period last year[9] - Total profit increased by 400.52% year-on-year, driven by sales growth, fair value changes, and asset disposal gains[22] - Operating revenue for the current period reached 1,178,428,715.03 CNY, an increase of 25.5% from 938,940,139.29 CNY in the previous period[79] - Operating profit decreased to 304,656,173.36 CNY, down 24.2% from 402,040,527.49 CNY in the previous period[79] - Net profit for the current period was 261,248,442.25 CNY, a decline of 25.1% compared to 349,057,674.50 CNY in the previous period[82] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,954,292,597.48, an increase of 4.60% compared to the previous year[9] - Total liabilities amounted to ¥3,586,103,862.66, up from ¥3,485,909,979.15, indicating an increase of around 2.9%[44] - Current liabilities totaled ¥3,114,359,993.61, slightly up from ¥3,087,614,440.35, showing a growth of about 0.9%[44] - Shareholders' equity increased to ¥3,368,188,734.82 from ¥3,162,392,191.67, representing a rise of approximately 6.5%[47] - Total liabilities increased to ¥2,674,299,583.85 from ¥2,462,051,560.38, marking a rise of 8.6%[57] - The company reported a total asset value of 6,648,302,170.82, unchanged from the previous period, indicating stability in asset management[98] Cash Flow - Cash flow from operating activities was ¥115,715,219.63, down 42.50% compared to the previous year[9] - The company’s cash flow from operating activities improved, contributing positively to the overall financial health[62] - The cash flow from operating activities was 256,139,880.90 CNY, a decrease of 7.9% from 278,158,457.04 CNY in the previous period[85] - The net cash flow from operating activities was -97,642,848.93, compared to 148,032,764.66 in the previous period, indicating a significant decline in operational cash generation[91] - Cash inflow from financing activities was 2,093,410,260.00, slightly down from 2,152,099,230.65 in the previous period, indicating stable financing operations[91] Expenses and Costs - Financial expenses surged by 799.07% year-on-year, mainly due to increased foreign exchange losses[22] - The company’s financial expenses rose to ¥56,335,093.89 from ¥52,942,719.39, reflecting increased borrowing costs[72] - The total operating costs for the current period were ¥2,364,034,947.03, up from ¥1,966,773,998.04 in the previous period, representing a 20.2% increase[72] - Research and development expenses for the current period were ¥22,093,270.69, compared to ¥19,866,421.16 in the previous period, indicating a growth of 11.5%[58] - Research and development expenses increased to 38,014,618.63 CNY, up 33.2% from 28,564,512.14 CNY in the previous period, indicating a focus on innovation[79] Shareholder Information - The total number of shareholders at the end of the reporting period was 65,078, with the top ten shareholders holding significant stakes[14] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[18] Other Financial Metrics - The weighted average return on net assets was 5.49%, an increase from 4.34% in the previous year[9] - Other comprehensive income increased by 47.46% compared to the beginning of the period, mainly due to foreign currency exchange differences[22] - The company received government subsidies amounting to ¥26,567,428.16 during the reporting period[9] - The company reported a gross profit margin of approximately 15.6% for the current period, compared to 10.4% in the previous period[58] - The company recorded a fair value gain of 20,772,617.61 CNY, compared to a loss of 21,975,660.00 CNY in the previous period, indicating a positive shift in asset valuation[79]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2019, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders was 200 million RMB, up 10% compared to the same period last year[19]. - The company aims to achieve a revenue target of 2.5 billion RMB for the full year 2019, reflecting a growth rate of 12%[19]. - The company's operating revenue for the current period is ¥1,680,639,089.40, representing a 29.81% increase compared to ¥1,294,705,336.37 in the same period last year[26]. - Net profit attributable to shareholders decreased by 60.85% to ¥141,818,695.02 from ¥362,270,999.89 year-on-year[26]. - The net profit after deducting non-recurring gains and losses increased by 62.00% to ¥139,792,147.83 compared to ¥86,293,220.36 in the previous year[26]. - The company achieved a sales revenue of RMB 168,063.91 million, representing a year-on-year growth of 29.81%[50]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 13,979.21 million, an increase of 62% compared to the same period last year[49]. Investment and R&D - The company plans to invest 300 million RMB in R&D for new product development and technology upgrades in 2019[19]. - The company’s research and development investment was RMB 60,591.94 million, showing a slight increase of 0.03% compared to the previous year[58]. - The company applied for 10 new invention patents and obtained 7 new authorizations during the reporting period, bringing the total number of applied patents to 132, with 85 authorized[53]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a budget of 500 million RMB allocated for potential deals[19]. Market Expansion - User data indicates a 20% increase in active users for the company's main products over the past six months[19]. - The company has expanded its market presence in Southeast Asia, achieving a 25% growth in sales in that region[19]. - A new product line in the pharmaceutical sector is expected to launch in Q4 2019, projected to contribute an additional 100 million RMB in revenue[19]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[63]. Financial Position - Total assets at the end of the current period amounted to ¥6,890,254,028.39, a 3.64% increase from ¥6,648,302,170.82 at the end of the previous year[26]. - The company's net assets attributable to shareholders increased by 0.70% to ¥3,029,273,192.67 from ¥3,008,215,708.40 at the end of the previous year[26]. - The company reported non-recurring losses of ¥2,658,748.55 from the disposal of non-current assets and a government subsidy of ¥20,789,139.84[29]. - The company’s total liabilities increased significantly, with other payables rising by 221.61% to RMB 204,663.08 million, mainly due to the provision for dividends[58]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[129]. - The total discharge of COD is 30.86, with a maximum allowable discharge of 32.78[129]. - The total discharge of ammonia nitrogen is 5.21, with a maximum allowable discharge of 6.34[129]. - The company has established a set of air pollution control facilities with a processing capacity of 15,000 m³/h, utilizing plasma + photocatalytic oxidation + absorption technology, which is also functioning normally[136]. Shareholder Information - The company reported a total of 820,093,827 shares outstanding, with 34.35% being restricted shares prior to the recent changes[151]. - Major shareholders include Wang Yingmei with 19.65% and He Renbao with 13.58% of the shares, both of whom are related[156]. - The company has 65,082 common stock shareholders as of the end of the reporting period[156]. - The company’s major shareholder, China Medical Industry Development Group, had 14,351,615 shares released from restrictions on May 15, 2019[155]. Risks and Challenges - The company is facing potential risks related to regulatory changes in the pharmaceutical industry, which may impact future operations[6]. - Fluctuations in raw material prices have been noted, potentially affecting gross margins, but the company is implementing measures to stabilize procurement costs[88]. - The company faces foreign exchange risks due to its export sales primarily being settled in USD, which could impact revenue and costs[91].

Financial Performance - The company's operating revenue for Q1 2019 was ¥737,707,368.38, representing a 19.98% increase compared to ¥614,848,462.37 in the same period last year[9]. - Net profit attributable to shareholders was ¥112,030,352.36, up 30.65% from ¥85,750,663.28 year-on-year[9]. - Basic and diluted earnings per share were both ¥0.1366, reflecting a 31.35% increase from ¥0.104 in the same period last year[9]. - Operating income increased by 104.71% compared to the previous period, also due to increased government subsidies[24]. - The total comprehensive income for the current period was ¥108,045,086.59, compared to ¥82,940,143.25 in the previous period, reflecting a 30.5% increase[61]. - The total profit for the current period is approximately ¥133.66 million, compared to ¥96.23 million in the previous period, representing an increase of 38.9%[65]. - The net profit for the current period is approximately ¥113.61 million, up from ¥82.61 million in the previous period, reflecting a growth of 37.5%[65]. Cash Flow - The net cash flow from operating activities surged to ¥31,294,478.62, a significant increase of 93,752.61% compared to ¥33,344.28 in the previous year[9]. - Cash inflows from operating activities reached approximately ¥771.65 million, compared to ¥464.44 million in the previous period, indicating a significant increase of 66.0%[67]. - The net cash flow from operating activities is approximately ¥31.29 million, a slight decrease from ¥33.34 million in the previous period[73]. - Cash inflows from financing activities amounted to approximately ¥1.16 billion, compared to ¥1.09 billion in the previous period, an increase of 6.6%[73]. - The net cash flow from financing activities is approximately -¥22.23 million, a decline from a positive net flow of ¥49.85 million in the previous period[73]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,856,397,401.11, a 3.13% increase from ¥6,648,302,170.82 at the end of the previous year[9]. - The total liabilities increased to CNY 3,574,554,622.83 from CNY 3,485,909,979.15, reflecting a growth of approximately 2.5%[41]. - The total owner's equity rose to CNY 3,281,842,778.28 from CNY 3,162,392,191.67, indicating an increase of about 3.8%[44]. - The company's cash and cash equivalents increased to CNY 394,097,448.52 from CNY 343,333,660.39, representing a growth of approximately 14.8%[45]. - The total current liabilities amounted to CNY 3,113,922,502.31, up from CNY 3,087,614,440.35, showing a slight increase of about 0.8%[41]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 67,935[14]. - The largest shareholder, Wang Yingmei, holds 19.65% of the shares, with a total of 161,150,400 shares[14]. Expenses - Research and development expenses rose by 52.54% compared to the previous period, reflecting increased investment in R&D[24]. - Sales expenses increased by 38.83% compared to the previous period, primarily due to higher freight costs associated with sales growth[24]. - The company reported a 46.87% decrease in financial expenses compared to the previous period, attributed to reduced exchange losses from currency fluctuations[24]. Other Income - The company reported a non-operating income of ¥78,294,289.16 from fair value changes of financial assets, excluding normal business operations[9]. - The company received government subsidies amounting to ¥7,565,370.15 during the reporting period[9]. - Other income grew by 122.61% compared to the previous period, due to an increase in government subsidies received[24]. - The company received approximately ¥37.24 million in investment income during the current period, compared to ¥3.02 million in the previous period, marking a substantial increase of 1,134.4%[73].

Financial Performance - The company's operating revenue for 2018 was ¥3,295,273,792.63, representing a 19.78% increase from ¥2,751,122,306.66 in 2017[26]. - The net profit attributable to shareholders for 2018 was ¥441,660,042.48, a significant increase of 142.36% compared to ¥182,236,146.97 in 2017[26]. - The net profit after deducting non-recurring gains and losses reached ¥140,980,765.18, marking a 1,357.73% increase from ¥9,671,224.84 in 2017[26]. - The net cash flow from operating activities surged to ¥719,671,411.03, a remarkable increase of 3,577.29% from ¥19,570,675.69 in 2017[26]. - Basic earnings per share for 2018 were ¥0.54, up 145.45% from ¥0.22 in 2017[26]. - Total assets at the end of 2018 amounted to ¥6,648,302,170.82, reflecting a 13.38% increase from ¥5,863,822,682.59 at the end of 2017[26]. - The net assets attributable to shareholders increased by 12.50% to ¥3,008,215,708.40 at the end of 2018, compared to ¥2,674,064,152.33 at the end of 2017[26]. - The company's revenue for the year 2018 was CNY 329,527.38 million, representing a year-on-year growth of 19.78%[54]. - The net profit attributable to the parent company was CNY 44,166.00 million, showing a significant increase of 142.36% compared to the previous year[54]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of 1.50 CNY per 10 shares based on a total of 820,093,827 shares, with no bonus shares issued[6]. - The profit distribution plan for 2018 includes a cash dividend of 1.5 yuan per 10 shares and a capital reserve increase of 1.2 shares per 10 shares[154]. - The total cash dividend for 2018 amounts to 123,014,074.05 yuan, representing 27.85% of the net profit attributable to ordinary shareholders[155]. - The company plans to distribute at least 20% of profits as cash dividends in future periods, in line with its three-year dividend return plan[160]. - The company has committed to a minimum cumulative net profit of ¥180 million, ¥270 million, and ¥450 million for the years 2016, 2017, and 2018 respectively, with cash compensation required if actual profits fall below 70% of these commitments[161]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[5]. - The company will continue to monitor macroeconomic conditions and adjust strategies accordingly to minimize risks[147]. - Environmental protection costs may increase due to stricter regulations, potentially impacting performance, but could also create new market opportunities[144]. - Fluctuations in raw material prices may affect gross margins, but the company will implement measures to stabilize procurement costs[145]. - Exchange rate fluctuations pose risks to export revenues and costs, with measures in place to mitigate these impacts[146]. - Economic uncertainties may affect sales, prompting the company to enhance market development and R&D investments[147]. Research and Development - The company increased R&D investment to CNY 129.97 million in 2018, a year-on-year growth of 34.30%[61]. - Research and development expenses for 2018 were ¥95,560,838.22, a 44.62% increase from ¥66,077,541.44 in 2017, aimed at enhancing product competitiveness[87]. - The proportion of R&D investment to operating revenue was 3.94%, up from 3.52% in 2017[91]. - The company has established a research institute focused on cutting-edge technology research and development, aiming to create new profit growth points[90]. Acquisitions and Investments - The company acquired 85% of Jiangsu Subin for CNY 17 million, enhancing its vertical integration in the pesticide sector[65]. - The company also acquired 100% of Binhai Meikang for CNY 6.18 million to bolster its pharmaceutical production capacity[65]. - The company completed the acquisition of 100% equity in Binhai Meikang Pharmaceutical Co., Ltd. for a total consideration of CNY 61,816,000[105]. - The company acquired Jiangsu Subin and Binhai Meikang through cash purchases to expand its vertical integration in the pesticide and pharmaceutical intermediate sectors[124]. Operational Efficiency - The company reported a net cash flow from operating activities that increased steadily throughout the year, indicating improved management of accounts receivable[34]. - The company’s cash and cash equivalents increased, reflecting improved liquidity and operational efficiency[176]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[173]. - The company has maintained a standard audit report with no significant accounting errors requiring retrospective restatement[179]. Environmental and Safety Standards - Environmental protection expenditures for the year amounted to CNY 3,351.60 million, an increase of 5.80% year-on-year, while safety expenditures reached CNY 1,506.09 million, up 8.86%[59]. - The company will continue to optimize and innovate processes, enhance safety and environmental management, and ensure stable operations[138]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the electronic chemicals and pharmaceutical sectors[18]. - The company continues to focus on the fluorinated fine chemical industry, emphasizing market expansion and product development as key strategies for growth[54]. - The company aims to enhance its management, R&D capabilities, and environmental standards while expanding market reach, particularly with key customers[133]. - The company plans to accelerate the industrialization of key projects, including obtaining FDA approval for Yongtai Pharmaceutical's formulations to release production capacity[136]. Shareholder Relations - The company has established a dedicated investor relations team to facilitate communication with shareholders and stakeholders[20]. - The company’s financial disclosures are published in designated media, ensuring compliance with regulatory requirements[21]. - The company has ensured strict adherence to all commitments made regarding performance and profit distribution, as confirmed by the audit reports[161].

浙江永太科技股份有限公司 2018 年第三季度报告正文 证券代码：002326 证券简称：永太科技 公告编号：2018-094 浙江永太科技股份有限公司 2018 年第三季度报告正文 1 浙江永太科技股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 非经常性损益项目和金额 √ 适用 □ 不适用 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江永太科技股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 6,712,274,089.34 | 5,863,822, ...

浙江永太科技股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 浙江永太科技股份有限公司 2018 年半年度报告全文 浙江永太科技股份有限公司 2018 年半年度报告 股票代码：002326 公司简称：永太科技 报告日期：2018 年 8 月 25 日 1 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中涉及未来计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。公司在本报告第四节"经营情况讨论与 分析"中"十、公司面临的风险和应对措施"描述了公司经营中可能面临的风险， 敬请投资者关注相关内容，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释 ...

浙江永太科技股份有限公司 2018 年第一季度报告全文 浙江永太科技股份有限公司 2018 年第一季度报告 2018 年 04 月 1 浙江永太科技股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江永太科技股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 614,848,462.37 | 526,825,475.21 | 16.71% | | 归属于上市公司股东的净利润（元） | 85,750,663.28 | 164,292 ...

浙江永太科技股份有限公司 2017 年年度报告全文 浙江永太科技股份有限公司 2017 年年度报告 2018 年 03 月 1 浙江永太科技股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第四节"经营情况讨论与分析"中"公司未来发展的展望"部 分，具体描述了公司经营过程中可能存在的风险及应对措施，敬请投资者关注 相关内容。 公司经本次董事会审议通过的利润分配预案为：以 822,376,427 为基数，向 全体股东每 10 股派发现金红利 1.00 元（含税），送红股 0 股（含税），不以公积 金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 6 | | ...

浙江永太科技股份有限公司 2017 年第三季度报告正文 证券代码：002326 证券简称：永太科技 公告编号：2017-74 浙江永太科技股份有限公司 2017 年第三季度报告正文 1 浙江永太科技股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江永太科技股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 项目界定为经常性损益的项目的情形。 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 总资产（元） | 5,977,255,121.90 | | 4 ...

浙江永太科技股份有限公司 2017 年半年度报告全文 浙江永太科技股份有限公司 2017 年半年度报告 公司负责人王莺妹、主管会计工作负责人陈丽洁及会计机构负责人(会计主 管人员)倪晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 股票代码：002326 公司简称：永太科技 报告日期：2017 年 8 月 18 日 1 浙江永太科技股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 本半年度报告中涉及未来计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。 公司在本报告第四节"经营情况讨论与分析"中"十、公司面临的风险和应对 措施"描述了公司经营中可能面临的风险，敬请投资者关注相关内容，注意投资 风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | ...